Growth hormone deficiency (GHD) is a medical condition due to not enough growth hormone (GH). ... Some cases are associated with a lack of other pituitary hormones, in which case it is known as combined pituitary hormone deficiency. Diagnosis involves blood tests to measure growth hormone levels.
This report contains market size and forecasts of Growth Hormone Deficiency Therapy in Global, including the following market information:
Global Growth Hormone Deficiency Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Growth Hormone Deficiency Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Parenteral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Growth Hormone Deficiency Therapy include Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Growth Hormone Deficiency Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Growth Hormone Deficiency Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Growth Hormone Deficiency Therapy Market Segment Percentages, by Type, 2021 (%)
Parenteral
Transdermal
Oral
Others
Global Growth Hormone Deficiency Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Growth Hormone Deficiency Therapy Market Segment Percentages, by Application, 2021 (%)
Hospitals
Drugstores
Others
Global Growth Hormone Deficiency Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Growth Hormone Deficiency Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Growth Hormone Deficiency Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Growth Hormone Deficiency Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Pfizer
AbbVie
Novo Nordisk
Merck KGaA
Mylan
Bayer
Teva
Novartis
Abbott
Roche
Endo International
Ipsen
ANI Pharmaceuticals
TherapeuticsMD